Adial Pharmaceuticals, Inc
ADIL
Health Care
1
exclusion reason
1 theme
This page is part of our public exclusion list — a transparency tool that shows which companies we screen out and why. It is not investment advice, and it is not an accusation. But it is subject to change as our understanding of the facts evolves.
Adial Pharmaceuticals is a clinical-stage biopharmaceutical company developing AD04 (ondansetron), a selective serotonin-3 receptor antagonist, for the treatment of Alcohol Use Disorder. The company’s primary investigational drug candidate has progressed through Phase 3 clinical trials, a development process that inherently involves animal testing to satisfy regulatory requirements for safety and efficacy prior to human trials. Preclinical studies for such pharmaceutical candidates typically utilize animal models to assess pharmacokinetics, toxicology, and therapeutic potential. As a company whose core value proposition is tied to advancing a novel therapeutic through the FDA approval pathway, Adial’s research and development operations are structurally reliant on animal-based testing protocols.
Research Sources
1 organization
Related Exclusions
Wondering what we do invest in?
The Naughty List
A digest of changes to our exclusion list — new additions, removals, and the evidence behind them. We review the list continuously as new evidence surfaces.
Companies appear on our exclusion list based on our investment judgment — not because they've done anything illegal. This is a difference of values and opinion, not an accusation of wrongdoing. Exclusion does not constitute a recommendation against investing in any company, and absence from the list does not constitute a recommendation to invest.
This information is provided for educational and transparency purposes only and should not be relied upon as investment advice. Data is drawn from independent watchdogs, NGOs, government registries, and Ethical Capital's ongoing research — see Research Sources for the full list.
Ethical Capital LLC is a state-registered investment adviser in Utah (CRD #316032). Registration does not imply a certain level of skill or training.